p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells

Oncogene

Volumn 27, Issue 30, 2008, Pages 4161-4171

  Toscano, F ^a,b   Fajoui, Z El ^a,b   Gay, F ^a,b   Lalaoui, N ^c,d   Parmentier, B ^a,b   Chayvialle, J A ^a,b   Scoazec, J Y ^a,b   Micheau, O ^c,d   Abello, J ^a,b   Saurin, J C ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Chu   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Antagonism; DcR1 colon cancer; Oxaliplatin; p53; TRAIL

Indexed keywords

CASPASE 3; CELL RECEPTOR; OXALIPLATIN; PROTEIN DCR1; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN INDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; COLONIC NEOPLASMS; DRUG ANTAGONISM; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; MUTANT PROTEINS; ORGANOPLATINUM COMPOUNDS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 47049096316     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.52     Document Type: Article

References (39)

1. Ashkenazi A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430.
2. Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A. (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 89: 206-214.
3. Bouralexis S, Findlay DM, Evdokiou A. (2005). Deathto the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 10: 35-51.
4. Chou TC, Talalay P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
5. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G et al. (2005). Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 102: 18099-18104.
6. Davidovich IA, Levenson AS, Levenson Chernokhvostov VV. (2004). Overexpression of DcR1 and survivin in genetically modified cells withpleiotropic drug resistance. Cancer Lett 211: 189-197.
7. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. (2005). Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 4: 2026-2036.
8. Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P et al. (2001). Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20: 5025-5032.
9. Grady WM, Markowitz SD. (2002). Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3: 101-128.
10. Gramont A. (2005). Adjuvant therapy of stage II and III colon cancer. Semin Oncol 32: 11-14.
11. He Q, Huang Y, Sheikh MS. (2004). Proteasome inhibitor MG132 upregulates deathreceptor 5 and cooperates with Apo2L/T RAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 23: 2554-2558.
12. Jang SH, Seol JY, Kim CH, Yoo CG, Kim YW, Han SK et al. (2004). Additive effect of TRAIL and p53 gene transfer on apoptosis of human lung cancer cell lines. Int J Mol Med 13: 181-186.
13. Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z et al. (2004). Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growthand improve survival. Cancer Res 64: 4900-4905.
14. Kelley SK, Ashkenazi A. (2004). Targeting death receptors in cancer with Apo2L/TRAI L. Curr Opin Pharmacol 4: 333-339.
15. Kim YH, Park JW, Lee JY, Kwon TK. (2004). Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25: 1813-1820.
16. LeBlanc HN, Ashkenazi A. (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75.
17. Liu X, Yue P, Khuri FR, Sun SY. (2005). Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 65: 9169-9175.
18. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. (2006). Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26: 7046-7055.
19. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. (2007). TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 11: 1299-1314.
20. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. (1999). Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 274: 7987-7992.
21. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. (2001). NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21: 5299-5305.
22. Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA et al. (2006). A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients withmetastatic colorectal cancer. Ann Oncol 17: 313-321.
23. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R et al. (2005). Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 11: 3126-3135.
24. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. (2000). Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853.
25. Oren M. (2003). Decision making by p53: life, deathand cancer. Cell Death Differ 10: 431-442.
26. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. (1997). An antagonist decoy receptor and a deathdomain-contain ing receptor for TRAIL. Science 277: 815-818.
27. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C et al. (2005). HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell deathin multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430-1441.
28. Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A. (2004). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. J Biol Chem 279: 4093-4101.
29. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. (1999). Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 274: 22532-22538.
30. Shankar S, Srivastava RK. (2004). Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7: 139-156.
31. Sheikh MS, Fornace Jr AJ. (2000). Death and decoy receptors and p53-mediated apoptosis. Leukemia 14: 1509-1513.
32. Steel GG, Peckham MJ. (1979). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91.
33. Thorburn A. (2004). Death receptor-induced cell killing. Cell Signal 16: 139-144.
34. Toscano F, Parmentier B, Fajoui ZE, Estornes Y, Chayvialle JA, Saurin JC et al. (2007). p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells. Biochem Pharmacol 74: 392-406.
35. Van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H et al. (2006). Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 24: 4998-5004.
36. Vignati S, Codegoni A, Polato F, Broggini M. (2002). TRAIL activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 38: 177-183.
37. Wajant H, Gerspach J, Pfizenmaier K. (2005). Tumor therapeutics by design: targeting and activation of deathreceptors . Cytokine Growth Factor Rev 16: 55-76.
38. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. (2004). TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783.
39. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M et al. (2000). Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32: 482-490.